Literature DB >> 23972008

Antidepressant effects of botulinum toxin A: scientific rationale.

Eric Finzi.   

Abstract

Mesh：

Year:  2013        PMID： 23972008      PMCID： PMC3756121          DOI： 10.1503/jpn.130090

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  3 in total

1.  Facing depression with botulinum toxin: a randomized controlled trial.

Authors:  M Axel Wollmer; Claas de Boer; Nadeem Kalak; Johannes Beck; Thomas Götz; Tina Schmidt; Muris Hodzic; Ursula Bayer; Thilo Kollmann; Katja Kollewe; Daniela Sönmez; Katja Duntsch; Martin D Haug; Manfred Schedlowski; Martin Hatzinger; Dirk Dressler; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  J Psychiatr Res       Date:  2012-02-24       Impact factor: 4.791

2.  Treatment of depression with botulinum toxin A: a case series.

Authors:  Eric Finzi; Erika Wasserman
Journal:  Dermatol Surg       Date:  2006-05       Impact factor: 3.398

Review 3.  Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186
  3 in total
  1 in total

1.  Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression.

Authors:  Abbas Zamanian; Atefeh Ghanbari Jolfaei; Golnaz Mehran; Zahra Azizian
Journal:  Iran J Public Health       Date:  2017-07       Impact factor: 1.429
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.